Home » AUROBINDO'S GENERIC DRUG COMBINATION GETS TENTATIVE APPROVAL
AUROBINDO'S GENERIC DRUG COMBINATION GETS TENTATIVE APPROVAL
Aurobindo Pharma received tentative approval for a fixed-drug combination product containing Lamivudine150-mg and Zidovudine 300-mg tablets copackaged with Abacavir 300-mg tablets used in the treatment of HIV-1 infection. The three drugs are now available in one single pack.
This combination pack comprising two nucleoside reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor is cost effective and reduces the threat of resistance due to missed doses. This is the first FDA-approved three-drug combination pack.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May